Tecentriq

Active substance

atezolizumab

Holder

Roche

Status

Closed

Indication

locally advanced or metastatic urothelial carcinoma in adult, previously untreated patients who are considered cisplatin ineligible

Public documents

Approbation

Information for the patient

Informed consent

Last update

02/03/2018

Last updated on 13/02/2024